Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$8.23 USD
+0.60 (7.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.23 USD
+0.60 (7.86%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Zacks News
Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports.
Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
by Zacks Equity Research
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Vir Biotechnology, Inc. (VIR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 19.94% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
by Zacks Equity Research
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
Vir Biotechnology, Inc. (VIR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
by Zacks Equity Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
by Ekta Bagri
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
by Zacks Equity Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
VIR Stock Down on Another Setback for COVID-19 Antibody
by Zacks Equity Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
Vir Biotechnology, Inc. (VIR) Moves 14.8% Higher: Will This Strength Last?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VIR Stock Gains on News of Inclusion in the S&P SmallCap 600
by Zacks Equity Research
Vir Biotechnology (VIR) shares gain as the company is set to join the S&P SmallCap 600 effective prior to the opening of trading on Monday, Apr 4.
AstraZeneca (AZN) Gets EU Nod for COVID-19 Antibody Cocktail
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) Evusheld for the pre-exposure prophylaxis of COVID-19 infection in a broad patient population.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
by Zacks Equity Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
by Zacks Equity Research
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
by Zacks Equity Research
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.